NASDAQ:TRAW

Traws Pharma (TRAW) Stock Price, News & Analysis

Traws Pharma logo
$0.18 -0.06 (-23.91%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$0.19 +0.01 (+8.00%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Traws Pharma Stock (NASDAQ:TRAW)

Advanced

Key Stats

Today's Range
$0.17
▼
$0.23
50-Day Range
$0.18
▼
$0.63
52-Week Range
$0.17
▼
$3.23
Volume
381,861 shs
Average Volume
197,559 shs
Market Capitalization
$2.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.00
Consensus Rating
Reduce

Company Overview

Traws Pharma is a clinical-stage biopharmaceutical company developing medicines for viral diseases and cancer. Its research includes antiviral candidates aimed at respiratory infections such as COVID-19 and influenza, as well as treatments for cancer.

The company’s pipeline includes narazaciclib, an investigational CDK4/6 inhibitor being studied for cancer, and antiviral drug candidates designed to target SARS-CoV-2 and influenza. These products remain in development and are not established as approved treatments.

Traws Pharma was formed in 2024 through the combination of Trawsfynydd Therapeutics and Onconova Therapeutics; the combined company adopted the Traws Pharma name. Its predecessor, Onconova, had focused on developing cancer therapies.

AI Generated. May Contain Errors.

Traws Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

TRAW MarketRank™: 
2.144744160175 of 5 stars

Traws Pharma scored higher than 43% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Traws Pharma has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no strong buy ratings, no buy ratings, 4 hold ratings, and 1 sell rating.

  • Upside Potential

    Traws Pharma has a consensus price target of $1.00, representing about 471.4% upside from its current price of $0.18.

  • Amount of Analyst Coverage

    Traws Pharma has only been the subject of 1 research reports in the past 90 days.

  • Read more about Traws Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Traws Pharma are expected to remain at ($1.01) per share in the coming year.

  • Percentage of Shares Shorted

    4.87% of the float of Traws Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Traws Pharma has a short interest ratio ("days to cover") of 4.14.
  • Change versus previous month

    Short interest in Traws Pharma has recently decreased by 0.30%, indicating that investor sentiment is improving.
  • Dividend Yield

    Traws Pharma does not currently pay a dividend.

  • Dividend Growth

    Traws Pharma does not have a long track record of dividend growth.

  • News Sentiment

    Traws Pharma has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Traws Pharma this week, compared to 2 articles on an average week.
  • Search Interest

    2 people have searched for TRAW on MarketBeat in the last 30 days.
  • MarketBeat Follows

    7 people have added Traws Pharma to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Traws Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    8.73% of the stock of Traws Pharma is held by insiders.

  • Percentage Held by Institutions

    7.95% of the stock of Traws Pharma is held by institutions.

  • Read more about Traws Pharma's insider trading history.
Receive TRAW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Traws Pharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TRAW Stock News Headlines

Brokers Set Expectations for Traws Pharma FY2026 Earnings
I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
Traws Pharma (TRAW) vs. Its Competitors Financial Analysis
See More Headlines

TRAW Stock Analysis - Frequently Asked Questions

Traws Pharma's stock was trading at $1.13 on January 1st, 2026. Since then, TRAW shares have decreased by 84.5% and is now trading at $0.1750.

Traws Pharma, Inc. (NASDAQ:TRAW) issued its quarterly earnings results on Monday, November, 16th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.03.

Traws Pharma (TRAW) raised $67 million in an initial public offering (IPO) on Thursday, July 25th 2013. The company issued 5,166,667 shares at $12.00-$14.00 per share.

Shares of TRAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/16/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:TRAW
Previous Symbol
NASDAQ:TRAW
CIK
1130598
Employees
7
Year Founded
N/A

Price Target and Rating

High Price Target
$1.00
Low Price Target
$1.00
Potential Upside/Downside
+471.4%
Consensus Rating
Reduce
Rating Score (0-4)
1.80
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.58)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$9.17 million
Net Margins
N/A
Pretax Margin
-710.83%
Return on Equity
-23,868.92%
Return on Assets
-171.09%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.93
Quick Ratio
0.93

Sales & Book Value

Annual Sales
$2.79 million
Price / Sales
0.96
Cash Flow
$0.51 per share
Price / Cash Flow
0.34
Book Value
($0.07) per share
Price / Book
-2.50

Miscellaneous

Outstanding Shares
15,370,000
Free Float
14,026,000
Market Cap
$2.69 million
Optionable
No Data
Beta
1.67
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:TRAW) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners